"Antirheumatic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that are used to treat RHEUMATOID ARTHRITIS.
| Descriptor ID |
D018501
|
| MeSH Number(s) |
D27.505.954.329
|
| Concept/Terms |
Antirheumatic Agents- Antirheumatic Agents
- Anti-Rheumatic Drugs
- Anti Rheumatic Drugs
- Antirheumatic Drugs
- Anti-Rheumatic Agents
- Anti Rheumatic Agents
Antirheumatic Drugs, Disease-Modifying- Antirheumatic Drugs, Disease-Modifying
- Antirheumatic Drugs, Disease Modifying
- DMARD
- Disease-Modifying, Antirheumatic Second-Line Drugs
- Disease Modifying, Antirheumatic Second Line Drugs
- Antirheumatic Disease-Modifying Second-Line Drugs
- Antirheumatic Disease Modifying Second Line Drugs
- Disease-Modifying Antirheumatic Drugs
- Disease Modifying Antirheumatic Drugs
|
Below are MeSH descriptors whose meaning is more general than "Antirheumatic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antirheumatic Agents".
This graph shows the total number of publications written about "Antirheumatic Agents" by people in this website by year, and whether "Antirheumatic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2004 | 2 | 1 | 3 |
| 2005 | 2 | 0 | 2 |
| 2007 | 3 | 0 | 3 |
| 2008 | 0 | 1 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 1 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 4 | 0 | 4 |
| 2016 | 5 | 2 | 7 |
| 2017 | 122 | 36 | 158 |
| 2018 | 121 | 40 | 161 |
| 2019 | 37 | 19 | 56 |
| 2020 | 67 | 41 | 108 |
| 2021 | 32 | 20 | 52 |
To return to the timeline, click here.
Below are the most recent publications written about "Antirheumatic Agents" by people in Profiles.
-
Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study. J Clin Rheumatol. 2022 03 01; 28(2):e348-e352.
-
Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. Arthritis Rheumatol. 2022 02; 74(2):284-294.
-
Arrhythmogenesis and COVID-19. Cardiol Rev. 2021 Nov-Dec 01; 29(6):289-291.
-
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. Rheumatology (Oxford). 2021 10 09; 60(SI):SI25-SI36.
-
The influence of the SARS-CoV-2 lockdown on patients with inflammatory rheumatic diseases on their adherence to immunomodulatory medication: a cross sectional study over 3 months in Germany. Rheumatology (Oxford). 2021 10 09; 60(SI):SI51-SI58.
-
Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark. Rheumatology (Oxford). 2021 10 09; 60(SI):SI59-SI67.
-
The role of immunomodulatory medications in the treatment of COVID-19. Curr Opin Rheumatol. 2021 09 01; 33(5):431-445.
-
Editorial: Rheumatology at the center of coronavirus disease 2019: pathogenesis, treatment, and clinical care. Curr Opin Rheumatol. 2021 09 01; 33(5):409-411.
-
Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic Turk J Med Sci. 2021 08 30; 51(4):1615-1623.
-
Patients with Rheumatic Diseases Overlooked during COVID-19 Pandemic: How are They Doing and Behaving? Curr Rheumatol Rev. 2021 Aug 30; 17(3):318-326.